Capital Fund Management (CFM)
TEVA icon

Capital Fund Management (CFM)’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Fund Management (CFM)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.48M Buy
215,200
+35,200
+20% +$1.13M 0.03% 766
2025
Q4 		$5.62M Sell
180,000
-116,700
-39% -$2.87M 0.02% 1128
2025
Q3 		$5.99M Buy
296,700
+18,600
+7% +$327K 0.02% 1140
2025
Q2 		$4.66M Buy
278,100
+257,300
+1,237% +$4.15M 0.01% 1183
2025
Q1 		$320K Sell
20,800
-500
-2% -$8.93K ﹤0.01% 1902
2024
Q4 		$469K Buy
21,300
+5,800
+37% +$106K ﹤0.01% 1920
2024
Q3 		$279K Sell
15,500
-41,600
-73% -$728K ﹤0.01% 1917
2024
Q2 		$928K Sell
57,100
-79,100
-58% -$1.22M ﹤0.01% 1629
2024
Q1 		$1.92M Buy
136,200
+91,400
+204% +$1.15M 0.01% 1460
2023
Q4 		$468K Buy
+44,800
New +$418K ﹤0.01% 1998
2019
Q1 		– Sell
-1,932,100
Closed -$29.8M – 2080
2018
Q4 		$29.8M Sell
1,932,100
-205,400
-10% -$4.21M 0.26% 82
2018
Q3 		$46M Buy
2,137,500
+151,200
+8% +$3.51M 0.25% 78
2018
Q2 		$48.3M Sell
1,986,300
-15,300
-0.8% -$312K 0.25% 102
2018
Q1 		$34.2M Sell
2,001,600
-1,742,400
-47% -$34M 0.21% 131
2017
Q4 		$70.9M Buy
3,744,000
+1,169,400
+45% +$17.6M 0.39% 50
2017
Q3 		$45.3M Buy
2,574,600
+1,305,100
+103% +$29.4M 0.33% 72
2017
Q2 		$42.2M Buy
1,269,500
+367,200
+41% +$11.4M 0.34% 69
2017
Q1 		$29M Buy
902,300
+418,000
+86% +$14.3M 0.24% 117
2016
Q4 		$17.6M Buy
484,300
+451,000
+1,354% +$18M 0.15% 184
2016
Q3 		$1.53M Buy
33,300
+16,400
+97% +$856K 0.01% 837
2016
Q2 		$849K Buy
+16,900
New +$900K 0.01% 1008
2016
Q1 		– Sell
-109,200
Closed -$7.17M – 1829
2015
Q4 		$7.17M Buy
109,200
+90,600
+487% +$5.6M 0.07% 352
2015
Q3 		$1.05M Sell
18,600
-261,900
-93% -$17M 0.01% 804
2015
Q2 		$16.6M Buy
280,500
+193,700
+223% +$11.9M 0.21% 127
2015
Q1 		$5.41M Sell
86,800
-95,600
-52% -$5.56M 0.07% 327
2014
Q4 		$10.5M Sell
182,400
-152,500
-46% -$8.5M 0.12% 221
2014
Q3 		$18M Sell
334,900
-243,800
-42% -$12.9M 0.2% 117
2014
Q2 		$30.3M Sell
578,700
-158,600
-22% -$8.11M 0.32% 60
2014
Q1 		$39M Buy
737,300
+725,500
+6,148% +$33.5M 0.48% 15
2013
Q4 		$473K Sell
11,800
-40,400
-77% -$1.59M 0.01% 1275
2013
Q3 		$1.97M Sell
52,200
-30,800
-37% -$1.2M 0.03% 651
2013
Q2 		$3.25M Buy
+83,000
New +$3.23M 0.05% 478

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Fund Management (CFM)'s TEVA Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 114,656 shares — an estimated $2.01M sold.

Capital Fund Management (CFM) first reported a position in TEVA in Q2 2013 and held it in 25 quarters. The position peaked at $52.3M in Q3 2016. 551 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Capital Fund Management (CFM) reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 114,656 Teva Pharmaceuticals shares in Q3 2025, an estimated $2.01M.
  • Capital Fund Management (CFM) first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • Capital Fund Management (CFM)'s Teva Pharmaceuticals position peaked at $52.3M in Q3 2016.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.